

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

DETERMINATION OF THE OFFER SIZE AND OFFER PRICE FOR THE A SHARE OFFERING

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 3 January 2019, 18 April 2019, 16 May 2019, 28 May 2019, 4 June 2019, 4 July 2019, 15 July 2019, 18 July 2019, 23 July 2019, 29 September 2019, 11 October 2019 and 17 October 2019 respectively, and the circular of the Company dated 25 February 2019, which include, among other things, matters related to the proposed A Share offering by the Company (the “**A Share Offering**”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and the circular.

The Board is pleased to announce that, following the completion of preliminary price consultations among inquiry targets on 16 October 2019, the Company will issue 17,800,000 A Shares at the issue price of RMB89.23 per A Share. The issue price was determined based on several factors including, among others, results of the preliminary price consultation, the number of shares to be issued, the fundamentals of the issuer, needs for proceeds, valuation of comparable companies, the industry in which the Company operates, market conditions and underwriting risks.

For the relevant terms of the A Share Offering, please refer to the full text of the Issue Announcement of Shanghai Haohai Biological Technology Co., Ltd. for the Initial Public Offering and Listing of Stocks on the Sci-Tech Innovation Board (《上海昊海生物科技股份有限公司首次公开发行人股票并在科创板上市发行公告》) published by the Company in Chinese only on the website of Shanghai Stock Exchange (www.sse.com.cn), the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.3healthcare.com) on 18 October 2019.

The Company will keep the Shareholders and potential investors informed of any further development in relation to the A Share Offering in accordance with the Listing Rules and applicable laws and regulations. This announcement is for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe of the securities of the Company.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC
18 October 2019

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company is Ms. You Jie; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Zhu Qin and Mr. Wong Kwan Kit.

* *For identification purpose only*